<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00336921</url>
  </required_header>
  <id_info>
    <org_study_id>L_9645</org_study_id>
    <nct_id>NCT00336921</nct_id>
  </id_info>
  <brief_title>Alfuzosin for Treating Acute Urinary Retention</brief_title>
  <official_title>A Double-blind, Randomized,Placebo Controlled Study of Alfuzosin 10mg od in the Return to Successful Voiding in Patients With a First Episode of Acute Urinary Retention Due to Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the efficacy of alfuzosin 10mg daily in the
      return to successful voiding after removal of the catheter following a first episode of acute
      urinary retention (AUR) in patients suffering from benign prostatic hyperplasia (BPH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with successful voiding after catheter removal</measure>
    <time_frame>Day 3 and 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From the beginning to the end of the study</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Acute Urinary Retention</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alfuzosin 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfuzosin</intervention_name>
    <description>Once daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First episode of painful AUR related to BPH requiring catheterization

          -  Residual volume between 500ml and 1500ml obtained at the time of catheterization and
             during the first one hour after catheterization

        Exclusion Criteria:

          -  Participated in another investigational study within 3 months before recruitment

          -  Suspect bladder neuro-dysfunction unrelated to etiology;

          -  Single Bladder neck disease;

          -  Acute/chronic prostatitis;

          -  Diagnosed prostate carcinoma;

          -  Suspected prostate carcinoma diagnosed by ultrasound wave;

          -  Surgical history of prostate and urethra;

          -  Diagnosed/suspected abnormality in urethra structure;

          -  Bladder stone;

          -  Blood urine retention caused by any reason;

          -  Residual volume less than 500 ml

          -  Residual volume more than 1500 ml

          -  AUR not due to BPH

          -  Parkinson's disease

          -  Insulin dependent diabetes

          -  Known/suspected multiple sclerosis;

          -  Stroke/MI within 6 months prior to enrolment;

          -  AST, ALT and Creatinine &gt; 1.5x upper limit; neutrophil &lt; 3,000/mm³; platelet &lt;
             100,000/mm³;

          -  Unstable/severe heart failure;

          -  History of postural hypertension/hypotension;

          -  Known hypersensitivity to α-receptor blocker;

          -  Suspected/diagnosed expansible nerval disease;

          -  Treatment with sympathomimetic agent within 1 week prior to enrolment, except OTC drug
             for cold intermittently;

          -  Treatment with α1-receptor blocker within 1 month prior to enrolment;

          -  Treatment with tricyclic antidepressants, anticholinergic agents, sympathomimetic
             agent (other than the above reason), first generation antihistaminic, except the
             treatment with stable β sympathomimetic agent/ anticholinergic agents lasting more
             than 1 week for Asthma and COPD (Chronic Obstructive Pulmonary Disease);

          -  Treatment with Disopyramide

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Jolain</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2006</study_first_submitted>
  <study_first_submitted_qc>June 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2006</study_first_posted>
  <last_update_submitted>September 14, 2009</last_update_submitted>
  <last_update_submitted_qc>September 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

